Above is from an earlier phase 2 trial with NE3107.
It is not easy to make sense of these results because the above figures show individual patients-- the n is super small.
Nonetheless, at least the trends are in the right direction.

What does the above model show (This figure is from the second url in the post two up)? The red line is the placebo line for the model calculated for the TB-2 trial as reported at CTAD 2023. This red line was based upon ~800 placebo and is likely known with high accuracy -- it is the natural progres...

OK, time to update NE3107. The headline type news for NE3107 was not that great --- there was a truly massive amount of fraud discovered when the trial was to report out. The giveaway should have been that they originally reported only blinded data at CTAD before more fully disclosing the phase 3 re...

Of course, there is yet more exciting news! FDA approved BrainSee for AD diagnosis on January 12th, 2024 as reported today on alzforum. Using AI to analyze a brain MRI, MMSe and CDR-sb score, this technology can predict conversion to AD with ~90% accuracy. Surprisingly, it does not appear to conside...

We are entering into the election season and it is probably a good time to get our Christmas list up to date. There is no point in waiting for Santa to ask us what we want for Christmas and tell the merry fellow that we will need to think about. We need an ask. What might that be? The obvious presen...